About Us | Vantage Biomedical Partners

Leadership

Meet the Founders

Founded by Arvind Ravinutala, MD and Aswini Ravinutala, BME, Vantage operates with a team of operators specializing in clinical, regulatory, and commercial intelligence.

Dr. Arvind Ravinutala

Co-Founder & Chief Medical Officer

MD | CMO, Fruit Street | P&T Chair, Medical Director & APD, Adventist Health

Dr. Arvind Ravinutala, MD — practicing physician and Medical Director with clinical informatics expertise. After seeing portfolio companies fail due to preventable regulatory and clinical missteps, he co-founded Vantage to bring clinical judgment into deal evaluation.

As Chief Medical Officer at Fruit Street, Dr. Ravinutala leads clinical strategy and represents the company to investors, the ADA, CDC, and Medicare Advantage partners. As P&T Committee Chair at Adventist Health White Memorial, he leads the committee that decides which therapeutics, devices, and diagnostics get adopted at the hospital. As Medical Director, he oversees clinical operations and quality initiatives across the department. As Associate Program Director for the Internal Medicine Residency, he trains resident physicians and watches firsthand how they evaluate and adopt new technologies across all modalities. He also serves on the Scientific Advisory Board of Spiro Medical, a $67M-funded company developing a first-of-its-kind Pulmonary Neuromodulation System for severe asthma, led by former Axonics COO Rinda Sama, who also serves as Vantage's Senior Advisor. This combination — C-suite leadership, formulary and therapeutic/device/diagnostic adoption decisions, clinical operations oversight, residency training, and active cross-vertical advisory — gives Dr. Ravinutala a physician's lens across devices, therapeutics, diagnostics, and digital health, making every Vantage assessment uniquely comprehensive.

Connect

Aswini Ravinutala

Co-Founder & Chief Technology Officer

BS Biomedical Engineering, UC Irvine | MSE Quality, Reliability & Statistical Engineering, Arizona State University

Aswini Ravinutala, BME — biomedical engineer with 8+ years in medical device development. Built manufacturing quality systems at Axonics (neuromodulation), led through the $4.1B acquisition to Boston Scientific. Currently R&D Manager at Spiro Medical. Brings engineering rigor and regulatory operations expertise.

Aswini has worked across life science companies that Vantage now evaluates. At Axonics, she was part of the operations engineering team that navigated the regulatory and manufacturing pathway leading to Boston Scientific's $4.1B acquisition — working on operational and quality frameworks for medical devices. At Vantage, she brings the biomedical engineering perspective to due diligence across all verticals: assessing manufacturing readiness, regulatory compliance maturity, and technical team capability for devices, therapeutics, diagnostics, biologics processing, and digital health platforms. Her areas of focus include manufacturing due diligence and supply chain risk assessment, regulatory and quality compliance assessment, design and verification strategy, regulatory pathway analysis, CMC readiness for pharma/biologics, and technical feasibility assessment for investors across all modalities.

Connect

How we think about diligence

Three lenses, applied to every score

Vantage is new. Our methodology is not — it's built from how hospital committees, MedTech operators, and engineers have always evaluated whether a device is real.

The physician lens

Hospital P&T committees ask three things before a new device touches a patient: Is it safer? Is it covered? Will staff actually use it? We score every company against the same three.

The operator lens

Promising MedTech dies in 510(k) review, supply-chain scaling, or post-launch reimbursement. Real diligence stress-tests all three failure modes — not just the one that made the deck look good.

The retrospective test

Before you trust a framework, see it run on cases everyone now agrees were knowable. Our case-study library applies the methodology to Theranos, Exactech, Pear, Owlet, Butterfly, and others — published, dated, no rewrites.

Start Quick Score — $2,500 See a sample report

Assessment Coverage

Integrated MD + BME Evaluation

Every assessment combines clinical insight with engineering rigor, creating a unified risk intelligence that neither discipline alone can provide.

Clinical Assessment

Physician Leadership

Adoption & Workflow

Will physicians actually use it in practice?

Regulatory & Reimbursement

Is there a viable path to approval and coverage?

Clinical Evidence

Does the data support the clinical claims?

Competitive Positioning

How does it stack up against alternatives?

+ Additional Proprietary Categories

Disclosed under NDA during engagement

Technical Assessment

Engineering Leadership

Manufacturing & Scale

Can it be built reliably at production volume?

Quality & Compliance

Are quality systems mature enough for regulatory scrutiny?

IP & Technical Risk

Is the technology defensible and differentiated?

Supply Chain & Operations

Are there hidden sourcing or dependency risks?

+ Additional Proprietary Categories

Disclosed under NDA during engagement

Integrated

Vantage Score

Clinical + Technical assessment unified into a single composite score

Life Science Verticals

8 Verticals Served

Our integrated MD + BME methodology applies across all modalities in the life science ecosystem.

1. Medical Devices

510(k), PMA, De Novo, predicate analysis, manufacturing readiness, reimbursement strategy

2. Therapeutics (Small Molecule)

IND pathway, clinical trial design, CMC readiness, drug-drug interactions, manufacturing scale-up

3. Biologics & Biosimilars

BLA pathway, cell line development, bioprocess scale-up, immunogenicity assessment, manufacturing controls

4. Diagnostics & IVD

CLIA waiver strategy, companion Dx, LDT compliance, clinical validation, analytical performance

5. Digital Health & SaMD

SaMD classification, cybersecurity, interoperability, real-world evidence, FDA/EMA pathways

6. Combination Products

Device + drug, device + biologic, drug delivery systems, primary mode determination, integrated pathways

7. Regenerative Medicine & Cell Therapy

Cell therapy manufacturing, REGEN-COV pathways, clinical manufacturing readiness, safety validation

8. Genomics & Molecular Diagnostics

Sequencing platforms, NGS validation, variant calling, CLIA waiver paths, clinical utility evidence

Senior Advisor

Specialist Leadership

Advisor

Rinda Sama

Senior Advisor, Medical Device Operations & Commercialization

Rinda brings C-suite operating experience from two successful Boston Scientific acquisitions. As COO of Axonics, he scaled operations from startup to the $4.1B acquisition. Previously, he led Vessix Vascular operations through its BSX acquisition. Now CEO of Spiro Medical and board member of UroMems, he provides perspective on what acquirers evaluate and what makes portfolio companies succeed post-acquisition. BME (USC) and MBA (UC Irvine).

His operational perspective on manufacturing readiness, regulatory compliance maturity, and post-acquisition integration directly informs our assessment methodology — bringing C-suite operating experience that enhances every evaluation.

Deep Domain Expertise

Built-In Clinical & Engineering Depth

Every engagement is led by our MD + BME founding team with direct device commercialization experience, guided by C-suite advisory from Rinda Sama. For assessments requiring additional category-specific clinical depth, physician specialist consultation is available.

Orthopedic & Musculoskeletal

Cardiovascular & Electrophysiology

Neurology & Neuromodulation

Digital Health & SaMD

Surgical Instruments & Robotics

Wound Care & Regenerative Medicine

Respiratory & Pulmonary

Urology & Pelvic Health

150+

Physician committee oversight spanning 150+ practitioners

Dr. Ravinutala serves as CMO at a digital health company, chairs the P&T Committee that decides device adoption at the hospital, is Medical Director overseeing clinical operations, is Associate Program Director for an Internal Medicine Residency, and sits on the SAB of a $67M neuromodulation company — bringing real-world adoption authority to every assessment

Documented Outcomes Database

Our proprietary analytical platform continuously refines risk stratification through 2,000+ documented outcomes

98%

Industry-Leading risk concordance

Proprietary risk stratification validated across 2,000+ biomedical companies, risk concordance validated against documented outcomes

Our Story

Why We Started Vantage

We saw the same pattern repeatedly: promising life science companies across all modalities — devices, therapeutics, diagnostics, biologics — failing not because of bad technology, but because of blind spots that specialized expertise could have identified early.

Investors were relying on generalist consultants who missed critical clinical adoption risks, regulatory complexities, and manufacturing challenges. Founders were getting advice that looked good on paper but fell apart when confronted with real-world realities in their specific vertical. The gap between comprehensive due diligence and actual life science success was costing everyone.

Vantage was built to close that gap. By combining a physician's understanding of clinical reality with a biomedical engineer's rigor on technical execution, we provide cross-vertical insight that actually predicts outcomes. Success patterns — and failure patterns — repeat across devices, therapeutics, diagnostics, and digital health. We're building the integrated dataset to prove it.

Our Competitive Advantage

The Vantage Difference

Every Vantage assessment is led by both a physician and a biomedical engineer working in parallel — integrating clinical, regulatory, engineering, and commercial risk into a single report. Our proprietary methodology provides cross-category pattern matching that improves with every engagement.

2-3 wk

Typical turnaround — faster than traditional firms

3-4

Concurrent engagement capacity

Device categories assessed to date

Our Methodology

Our Proprietary Analysis Framework

Our proprietary analytical platform combines structured human assessment with pattern-matching against life science outcomes curated from SEC filings, FDA and EMA records, clinical literature, and assessment engagements across devices, therapeutics, diagnostics, pharma, biologics, and digital health. Each engagement strengthens the model. The system is protected as trade secret intellectual property, continuously validated against real-world performance, market adoption, clinical efficacy, and reimbursement outcomes across all verticals.

See our full methodology →

The Vantage Team